A phase I trial of WRSS1, a Shigella sonnei live oral vaccine in Bangladeshi adults and children

• Autori principali: Rubhana Raqib (Autore), Protim Sarker (Autore), K. Zaman (Autore), Nur Haque Alam (Autore), Thomas F. Wierzba (Autore), Nicole Maier (Autore), Kaisar Talukder (Autore), Abdullah Hel Baqui (Autore), Akamol E. Suvarnapunya (Autore), Firdausi Qadri (Autore), Richard I. Walker (Autore), Alan Fix (Autore), Malabi M. Venkatesan (Autore)
• Natura: Libro
• Pubblicazione: Taylor & Francis Group, 2019-06-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Shigella sonnei live vaccine candidate, WRSS1, which was previously evaluated in US, Israeli and Thai volunteers, was administered orally to Bangladeshi adults and children to assess its safety, clinical tolerability and immunogenicity. In a randomized, placebo-controlled, dose-escalation, age-desce...